Online pharmacy Capsule raises $300M Series D at a valuation of $1B+, bringing its total raised to $570M
Angelica LaVito / Bloomberg : Tweets: @chrisbaglieri , @drugchannels , @angelicalavito , @aslanobahasan , and @1871chicago Tweets: Chris Baglieri / @chrisbaglieri : Momentous day @capsulecares. We're hiring on all the teams. We're growing in all the places. Help us bring life to a seamless, delightful and interconnected healthcare system. There's much to be done. https://www.bloomberg.com/... Adam J. Fein / @drugchannels : Stunning capital raise by a digital #pharmacy: @capsulecares gets another $300M and is now valued at $1 billion https://www.bloomberg.com/... VCs continue to bet big $$$ that the #pharmacy biz needs to be disrupted. @angelicalavito @business https://twitter.com/... @angelicalavito : Capsule raised $300 million, valuing the company at >$1 billion for the first time. The pharmacy wars are heating up https://www.bloomberg.com/... Hasan Aslanoba / @aslanobahasan : Online pharmacy Capsule raised $300 million in a round that CEO Eric Kinariwala said values the six-year-old startup company at more than $1 billion for the first time https://www.bloomberg.com/... via @business @1871chicago : Huge news from one of our members! 🎉 @capsulecares announced a big capital raise at a $1B valuation! They plans to use the funds to expand to new markets and invest in its technology. Congratulations Capsule! Read the news here: https://www.bloomberg.com/...
Context & Ripple Effects
This round completes the arc Capsule set out in its $50M 2018 raise, when the NYC online pharmacy said it would expand nationally within 12 to 18 months on the back of same-day delivery and real-time pharmacist access. Three years later it has converted that plan into unicorn status: $300M in Series D money lifts total funding to $570M.
The timing matters because Capsule is not raising into a vacuum — Ro pulled in $500M at a reported $5B valuation just weeks earlier, and Bloomberg's related coverage counts Alto, Medly, and Capsule together at $650M+ raised since January 2020, all aimed at incumbents CVS and Walgreens. Drug-channels analyst Adam J. Fein called the raise 'stunning' for a digital pharmacy, underscoring how unusual checks of this size still are in the category.
First-order effects
- Capsule now has roughly six times the capital it held after its 2018 round to fund the national footprint it promised then — hiring across teams, per CEO-adjacent commentary from Chris Baglieri, rather than defending a single metro market.
- Capsule enters the billion-dollar tier behind Ro's $5B, giving digital-pharmacy founders a valuation ladder when they next negotiate with VCs.
Second-order effects
- CVS and Walgreens now face three separately capitalized delivery-first challengers plus Amazon's PillPack acquisition in their core prescription business — forcing the chains to respond on convenience and pricing, not just store count.
- The round intensifies the fundraising race inside the category: with Alto, Medly, and Capsule alone past $650M since January 2020, laggard digital pharmacies must raise comparably or cede the delivery-speed war.
Third-order effects
- If mega-rounds keep flowing — Capital Rx later raised $400M including a $252M Series F in the same supply-chain corridor — prescription drug distribution is being recapitalized around venture-funded platforms, with scale capital as the entry ticket rather than brick-and-mortar networks.
- Sustained VC concentration in pharmacy could compress the field into a few delivery-first consolidators and push incumbent chains toward acquisitions or partnerships to acquire the software and logistics they lack.
The trend: Venture capital is recapitalizing US pharmacy retailing around delivery-first digital platforms, with each mega-round raising the capital threshold for challenging CVS and Walgreens.